HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yves Saint Laurent retires

This article was originally published in The Rose Sheet

Executive Summary

Fashion designer announces retirement in Paris Jan. 7. Retirement will result in the closing of YSL fashion house's couture business but will have little impact on the ready-to-wear business or fragrance and beauty license, which operate under Gucci. The rights to YSL ready-to-wear and beauty were acquired by the Pinault-Printemps-Redoute-owned Gucci for $1 bil. in 1999 from Artemis, a PPR holding company (1"The Rose Sheet" Nov. 22, 1999, p. 4). YSL fragrances include Opium, Kouros, Baby Doll and Nu, the most recent introduction that debuted in the fall (2"The Rose Sheet" July 16, 2001, p. 4)...

You may also be interested in...



YSL Nu Women's Fragrance To Be Unveiled Worldwide This Fall

When it bows worldwide this fall, Nu will be the first women's scent launched by Yves Saint Laurent since Tom Ford assumed creative control of the company last year and is the fragrance house's first introduction since 1999.

Gucci Acquires $583.4 Mil. Sanofi Beauty Business From Artemis

Gucci is purchasing Sanofi Beaute from Artemis for $1 bil., giving the fashion house Yves Saint Laurent fragrances and cosmetics, Roger & Gallet, and fragrance licenses for Van Cleef & Arpels, Oscar de la Renta, Fendi and Krizia. Sanofi beauty sales total $583.4 mil.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel